You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
OrbiMed Advisors | 0 | 10,425,225 | 0 | 10,425,225 | 10,425,225 | 32.87% |
OrbiMed Capital GP IV | 0 | 10,425,225 | 0 | 10,425,225 | 10,425,225 | 32.87% |
Samuel D. Isaly | 0 | 10,425,225 | 0 | 10,425,225 | 10,425,225 | 32.87% |
Follow Sam Isaly's OrbiMed Advisors
Page 1 of 12 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
CLEMENTIA PHARMACEUTICALS INC.
COMMON SHARES
185575107
OrbiMed Advisors LLC
OrbiMed Capital GP IV LLC
Samuel D. Isaly
601 Lexington Avenue, 54th Floor
New York, NY 10022
Telephone: (212) 739-6400
Authorized to Receive Notices and Communications)
August 21, 2017
Follow Clementia Pharmaceuticals Inc.
Follow Clementia Pharmaceuticals Inc.
Page 2 of 12 – SEC Filing
CUSIP No. 185575107 | ||||
1 | NAME OF REPORTING PERSON OrbiMed Advisors LLC | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ | ||
3 | SEC USE ONLY | |||
4 | SOURCE OF FUNDS N/A | |||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | ☐ | ||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | ||
8 | SHARED VOTING POWER 10,425,225 | |||
9 | SOLE DISPOSITIVE POWER 0 | |||
10 | SHARED DISPOSITIVE POWER 10,425,225 | |||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,425,225 | |||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | ☐ | ||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 32.87%* | |||
14 | TYPE OF REPORTING PERSON (See Instructions) IA |
Follow Clementia Pharmaceuticals Inc.
Follow Clementia Pharmaceuticals Inc.
Page 3 of 12 – SEC Filing
CUSIP No. 185575107 | ||||
1 | NAME OF REPORTING PERSON OrbiMed Capital GP IV LLC | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ | ||
3 | SEC USE ONLY | |||
4 | SOURCE OF FUNDS N/A | |||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | ☐ | ||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | ||
8 | SHARED VOTING POWER 10,425,225 | |||
9 | SOLE DISPOSITIVE POWER 0 | |||
10 | SHARED DISPOSITIVE POWER 10,425,225 | |||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,425,225 | |||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | ☐ | ||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 32.87%* | |||
14 | TYPE OF REPORTING PERSON (See Instructions) OO |
Follow Clementia Pharmaceuticals Inc.
Follow Clementia Pharmaceuticals Inc.
Page 4 of 12 – SEC Filing
CUSIP No. 185575107 | ||||
1 | NAME OF REPORTING PERSON Samuel D. Isaly | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ | ||
3 | SEC USE ONLY | |||
4 | SOURCE OF FUNDS N/A | |||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | ☐ | ||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION United States | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | ||
8 | SHARED VOTING POWER 10,425,225 | |||
9 | SOLE DISPOSITIVE POWER 0 | |||
10 | SHARED DISPOSITIVE POWER 10,425,225 | |||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 10,425,225 | |||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | ☐ | ||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 32.87%* | |||
14 | TYPE OF REPORTING PERSON (See Instructions) IN |
Follow Clementia Pharmaceuticals Inc.
Follow Clementia Pharmaceuticals Inc.
Page 5 of 12 – SEC Filing
Item 1. | Security and Issuer |
Item 2. | Identity and Background |
(i) | name; |
(ii) | business address; |
(iii) | present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; |
(iv) | citizenship. |
Follow Clementia Pharmaceuticals Inc.
Follow Clementia Pharmaceuticals Inc.
Page 6 of 12 – SEC Filing
Item 3. | Source and Amount of Funds or Other Consideration |
Item 4. | Purpose of Transaction |
Follow Clementia Pharmaceuticals Inc.
Follow Clementia Pharmaceuticals Inc.
Page 7 of 12 – SEC Filing
Item 5. | Interest in Securities of the Issuer |
Item 6. | Contracts, Arrangements, Understandings or Relationship with Respect to Securities of the Issuer |
Follow Clementia Pharmaceuticals Inc.
Follow Clementia Pharmaceuticals Inc.
Page 8 of 12 – SEC Filing
Follow Clementia Pharmaceuticals Inc.
Follow Clementia Pharmaceuticals Inc.
Page 9 of 12 – SEC Filing
Item 7. | Materials to Be Filed as Exhibits |
Exhibit | Description |
1. | Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital GP IV LLC and Samuel D. Isaly. |
2. | Form of Lock-Up Agreement (incorporated by reference to Exhibit A of Exhibit 1.1 to Amendment No. 1 to the Issuer’s Registration Statement on Form F-1 (SEC 333-219066), filed with the SEC on July 21, 2017). |
3. | Second Amended and Restated Registration Rights Agreement by and among the Issuer and each of the persons listed on Schedule A thereto, dated March 16, 2017 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form F-1 (SEC File No. 333-219066), filed with the SEC on June 30, 2017). |
Follow Clementia Pharmaceuticals Inc.
Follow Clementia Pharmaceuticals Inc.
Page 10 of 12 – SEC Filing
OrbiMed Advisors LLC | ||||
By: | /s/ Samuel D. Isaly | |||
Name: | Samuel D. Isaly | |||
Title: | Managing Member | |||
OrbiMed Capital GP IV LLC | ||||
By: | OrbiMed Advisors LLC its Managing Member | |||
By: | /s/ Samuel D. Isaly | |||
Name: | Samuel D. Isaly | |||
Title: | Managing Member | |||
Samuel D. Isaly | ||||
By: | /s/ Samuel D. Isaly | |||
Name: | Samuel D. Isaly | |||
Follow Clementia Pharmaceuticals Inc.
Follow Clementia Pharmaceuticals Inc.
Page 11 of 12 – SEC Filing
Name | Position with Reporting Person | Principal Occupation |
Samuel D. Isaly | Managing Member | Managing Member OrbiMed Advisors LLC |
Carl L. Gordon | Member | Member OrbiMed Advisors LLC |
Sven H. Borho German and Swedish Citizen | Member | Member OrbiMed Advisors LLC |
Jonathan T. Silverstein | Member | Member OrbiMed Advisors LLC |
W. Carter Neild | Member | Member OrbiMed Advisors LLC |
Geoffrey C. Hsu | Member | Member OrbiMed Advisors LLC |
Evan D. Sotiriou | Chief Financial Officer | Chief Financial Officer OrbiMed Advisors LLC |
Follow Clementia Pharmaceuticals Inc.
Follow Clementia Pharmaceuticals Inc.
Page 12 of 12 – SEC Filing
Exhibit | Description |
1. | Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital GP IV LLC and Samuel D. Isaly. |
2. | Form of Lock-Up Agreement (incorporated by reference to Exhibit A of Exhibit 1.1 to Amendment No. 1 to the Issuer’s Registration Statement on Form F-1 (SEC 333-219066), filed with the SEC on July 21, 2017). |
3. | Second Amended and Restated Registration Rights Agreement by and among the Issuer and each of the persons listed on Schedule A thereto, dated March 16, 2017 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form F-1 (SEC File No. 333-219066), filed with the SEC on June 30, 2017). |
13